Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II intravenous Trappsol Cyclo dose-ranging study in Niemann-Pick disease type C1
MOH_2017-09-17_000540Phase 2Completed
- Sponsor
- Cyclo Therapeutics, Inc.
- Start
- Jul 2017
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Trappsol Cyclo in Niemann-Pick disease type C1 (NPC1) (3 arms), sponsored by Cyclo Therapeutics, Inc. Primary endpoints: Safety and Pharmacokinetics. Started Jul 2017; status: completed.
02
Drugs
Trappsol Cyclo
03
Conditions
Niemann-Pick disease type C1 (NPC1)
Beyond the preview
Go deeper on MOH_2017-09-17_000540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-17_000540.